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Abstract
Effective immunity against Bordetella pertussis is currently under discussion following the
stacking evidence of pertussis resurgence in the vaccinated population. Natural immunity
is more effective than vaccine-induced immunity indicating that knowledge on infection-
induced responses may contribute to improve vaccination strategies. We applied a systems
biology approach comprising microarray, flow cytometry and multiplex immunoassays to
unravel the molecular and cellular signatures in unprotected mice and protected mice with
infection-induced immunity, around a B. pertussis challenge. Pre-existing systemic mem-
ory Th1/Th17 cells, memory B-cells, and mucosal IgA specific for Ptx, Vag8, Fim2/3 were
detected in the protected mice 56 days after an experimental infection. In addition, pre-
existing high activity and reactivation of pulmonary innate cells such as alveolar macro-
phages, M-cells and goblet cells was detected. The pro-inflammatory responses in the
lungs and serum, and neutrophil recruitment in the spleen upon an infectious challenge of
unprotected mice were absent in protected mice. Instead, fast pulmonary immune
responses in protected mice led to efficient bacterial clearance and harbored potential new
gene markers that contribute to immunity against B. pertussis. These responses comprised
of innate makers, such as Clca3, Retlna, Glycam1, Gp2, and Umod, next to adaptive mark-
ers, such as CCR6+ B-cells, CCR6+ Th17 cells and CXCR6+ T-cells as demonstrated by
transcriptome analysis. In conclusion, besides effective Th1/Th17 and mucosal IgA
responses, the primary infection-induced immunity benefits from activation of pulmonary
resident innate immune cells, achieved by local pathogen-recognition. These molecular
signatures of primary infection-induced immunity provided potential markers to improve
vaccine-induced immunity against B. pertussis.
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Introduction
The resurgence of pertussis in the vaccinated population prompts the necessity of more knowl-
edge on effective immunity against Bordetella pertussis [1, 2]. This global health problem
occurs after vaccination with acellular pertussis vaccines (aPV) and whole-cell pertussis vac-
cines (wPV) as recent data point out [3]. aPV-vaccinated individuals face waning immunity
early after vaccination, since the vaccine-induced immunity lasts for only 4–12 years [4, 5]
despite multiple booster vaccinations [6]. Moreover, research in baboons revealed that aPV-
vaccinated animals are protected against disease, but still harbor viable bacteria resulting in
continuation of pathogen transmission [7]. These findings indicate that even aPV-vaccinated
individuals may act as an important resource for the transmission of B. pertussis [8, 9]. Hence,
the present situation necessitates the reevaluation of pertussis immunity and vaccination
strategies.
The immunity induced by a B. pertussis infectionmay provide crucial information for
improving vaccine-induced immunity, since it provides important advantages compared to
immunity induced by aPV or wPV. Infection-induced immunity continues for a longer period
[4, 5] and it leads to sterilizing immunity in mice and baboons [7, 10]. Infection as well as aPV
and wPV vaccination induces strong systemic responses, but infection induces a mucosal
immune response at the site of pathogen entry in addition. As others and we recently showed,
this immunity includes pulmonary IgA, systemic IgG [10] and specific Th1/Th17 responses
[10–12]. The lungs are naturally exposed to pathogens and therefore equipped with an epithe-
lial layer and a large number of immune cells. The lung epithelial cells offer a first line of
defense by secretion of anti-microbial peptides and pathogen recognition, but also by interac-
tion with the local innate immune cells [13]. These innate immune cells include mucin-secret-
ing goblet cells [14], alveolar macrophages [15] and the upper layer of the bronchus-associated
lymphoid tissue (BALT) [16], that act in the same way as microfold (M)-cells [17], harbor
functions, such as pathogen recognition and antigen-uptake. These pulmonary innate cells
orchestrate the specific adaptive immune responses, such as mucosal IgA production and acti-
vation of tissue-resident B-cells and T-cells in the BALT [16].
In this study, we further explored the molecular and cellular events underlying infection-
induced protective immune responses. To this end, pulmonary transcriptomic profiles were
characterized around the challenge of mice protected by primary infection-induced immunity,
in comparison to events in unprotected counterparts. Additionally, pulmonary and systemic
cytokine profiles as well as cellular and antibodymediated immune responses against B. pertus-
sis were studied.Markers for pulmonary immunity included both trained innate and adaptive
signatures. M-cells, alveolar macrophages and epithelial cells characterized the former, and
CCR6+ B-cells, CCR6+ Th17 cells, CXCR6+ T-cells and mucosal IgA the latter. These extensive
insights into the signatures of infection-induced immunity involving important pulmonary
components may be used for the development of improved pertussis vaccines with long lasting
immunity.
Results
Pre-Existing Immunological Signatures in Protected Mice before B.
pertussis Challenge
Recovery from a B. pertussis infection in BALB/c mice is associated with sterilizing immunity.
A challenge with B. pertussis bacteria showed that the lungs were cleared within two days in
these protected mice, whereas this takes approximately 28 days in unprotected mice [10]. To
understand infection-inducedprotection in more detail we designed a systems biology
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approach to study pre- and post-challenge immune responses in unprotected and protected
mice, recovered from a primary infection received 56 days before (Fig 1A). Before the receiving
the challenge inoculum (D0), protected mice showed enhanced levels of B. pertussis-specific
serum IgG, mucosal IgA in the lungs, and Th1/Th17 cells in the spleen, which were absent in
naive (D0 unprotected) mice (Fig 1B). When comparing levels of pulmonary gene expression,
320 genes were still differentially expressed, mostly upregulated, in the lungs of protected com-
pared to naive (D0 unprotected) mice (S1 Table). An overrepresentation analysis (ORA) was
performed using DAVID [18] to ascribe the functional group to which the 320 corresponding
proteins belong (Fig 1C). The data analysis indicated that the pulmonary gene expression of
Fig 1. Design and baseline parameters of a B. pertussis challenge model in protected and naive unprotected mice. (A)
Schematic diagram of animal pre-treatment, sacrifice, sampling and systems analysis on 4 hours and 2, 7, 10 and 14 days p.c. in a B.
pertussis challenge model in protected and unprotected BALB/c mice. Pulmonary transcriptomic profile, percentage of splenic Gr1+
cells (neutrophils), serum and lung cytokine profiles, serum and lung antibody profiles, and specific splenic CD4+CD44+ T-cells were
assessed at the given time points in protected and unprotected mice. (B) Study parameters at baseline (D0) of naive unprotected mice
and protected mice, 56 days after primary infection, including time frames of lung clearance, systemic T-helper subsets, serum IgG
profile, mucosal IgA, and pulmonary transcriptomic profile as obtained from data in the current study and data adapted from our previous
study [10]. 320 genes are differential expressed in protected mice compared to naive (D0 unprotected) mice. (C) An overrepresentation
analysis was performed using DAVID for Keywords, KEGG-pathways, and gene ontology biological pathways (GO-BP) to determine the
function of the 320 genes. For each term, the number of upregulated (red) and downregulated (green) genes are depicted.
doi:10.1371/journal.pone.0164027.g001
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protected mice was enrichedwith 33 and 27 genes involved in immune response and defense
response, respectively. Upregulated genes were further involved in antigen processing, the
innate response and several terms indicating B-cell mediated immunity. Notably, a large num-
ber of both downregulated and upregulated genes were related to alternative splicing. In con-
clusion, these results indicated that the protected mice with infection-induced immunity
contain a large variety of adaptive and additionally still some innate markers to resist a new B.
pertussis challenge as compared to their unprotected naive counterparts.
Pulmonary Transcriptome of Protected and Unprotected Mice Receiving
a B. pertussis Challenge
To gain more insight into gene transcription patterns associated with fast clearance of B. per-
tussis and protection, we subsequently assessed the pulmonary transcriptome over a period of
14 days post challenge (p.c.) in protected and post infection (p.i.) in unprotected mice in com-
parison to naive non-challengedmice (unprotected D0) (Fig 2A). In total, 786 genes were dif-
ferentially regulated (p-value 0.001, fold ratio (FR) 1.5) (S1 Table). These genes were
divided in six clusters (I—VI) based on differential expression in unprotected and protected
mice (Fig 2). Cluster I: differential expression in unprotected mice, absent in protected mice;
cluster II: differential expression in both unprotected mice and protected mice; cluster III: dif-
ferential expression in unprotected mice and in protected mice pre- or post-challenge; cluster
IV: differential expression in unprotected mice and additional differential expression post-
challenge in protected mice; cluster V: absent in unprotected mice but differential expression
in protected mice; cluster VI: absent in unprotected mice but differential expression pre- and
post-challenge in protected mice.
The individual fold ratios (FR) of 786 differentially expressed genes were plotted for each
time point after being analyzed in protected and unprotected mice (S1A Fig). Before the chal-
lenge (D0), already 320 genes were differentially regulated in the protected mice if compared to
the unprotected mice. Furthermore, this analysis revealed that on 2 days p.c. the largest num-
ber of genes was differentially expressed between both groups, namely 212 genes of which 108
genes were upregulated and 104 were downregulated. Since the sterilizing immunity of pro-
tectedmice resulted in B. pertussis clearance within 2 days p.c. [10], signatures underlying this
immunity could be detected on 2 days p.c. in protected mice. Therefore, the transcriptomic
profiles of the 786 genes were investigated in detail on 2 days p.c. (Fig 2B). Subsequent to the
comparison of both datasets to naive mice, the fold ratios of each gene was calculated between
the datasets of unprotected versus protected mice obtained 2 days p.c. (FR 1.5 or 0.67, red
triangles) (Fig 2B). The scatter plot was divided in eight different fractions that were signifi-
cantly upregulated (1–4) or downregulated (5–8) in protected mice compared to unprotected
mice 2 days p.c. The genes of these fractions were shown as heatmaps (S1B Fig). Many genes
are involved in innate (e.g.A2m, Saa3, C3, Reg3g,Umod) and adaptive (e.g.Cd4, Ighg, Cxcr6,
Ccr6,Cd22) immune responses were upregulated in protected mice.
An ORA for KEGG pathways and GO-BP terms was performed on all 786 genes. In total,
97 terms were enriched (Benjamini 0.05). The number of upregulated and downregulated
genes and the kinetics for a subset of these terms was determined (Fig 2C and 2D). Enriched
terms contained genes involved in immune response (79 genes) including innate immune func-
tions such as acute phase (9 genes), antigen presentation (20 genes), chemotaxis (29 genes),
and pathogen recognition through the NOD-like receptor (11 genes). Moreover, terms incor-
porated in the adaptive immune response (16 genes) involved antibody response (16 genes),
IgA responses (13 genes) and T-cell activation (13 genes) (Fig 2D). The expression kinetics
were determined by averaging the FR for each time point for a selection of these enriched
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Fig 2. Pulmonary gene expression profiles in protected and unprotected mice following a B. pertussis challenge.
(A) Fold changes in gene expression of both unprotected and protected mice were calculated compared to naive mice (D0
unprotected). The expression results (FR1.5, p-value0.001) are visualized as heatmap (mean of n = 3). Genes not
exceeding a fold change of 1.5 are depicted as basal level (black) at this time point. In total, 786 genes were found to be
differentially regulated. Genes were divided in six clusters (I-VI) based on their expression profiles (color coding for these
clusters is depicted in an additional table): cluster I (Differential expression in unprotected mice, absent in protected mice),
Cluster II (Differential expression in unprotected mice and protected mice), Cluster III (Differential expression in
Signatures of Infection-Induced Pertussis Immunity
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terms (Fig 2C). This analysis showed that post-challenge in protected mice the immunoglobu-
lin-mediated immune response remained high (4h-D14). The complement response, antigen-
presentation, and T-cell activation were still moderately enhanced in protected mice. Further-
more, genes belonging to acute phase, cytokine responses, apoptosis and cell division were
expressed to a lesser extent upon challenge in protected mice than in unprotected mice.
While the ORA gave an insight in several functions involved upon challenge of protected as
well as unprotected mice, a large number of genes that were differentially regulated in our data-
set were not annotated. To obtain in depth information on the function of these genes, we per-
formed additional text mining on all individual genes using BioGPS, GeneRifs, and the
literature (Pubmed). Based on this information, selected genes could be grouped according to
function such as T-cell-related responses, B-cell-related responses, membrane receptors and
secreted proteins, as is described in more detail hereafter.
Gene expression of membrane receptors and secretedproteins. The gene expression
profiles of membrane receptors and secreted proteins indicated the involvement of specific cell
types and biological processes. Therefore, the expression of all genes encoding for membrane
proteins and secreted proteins was further investigated (Fig 3) and divided in four groups
(Group A-D), based on their expression profiles in unprotected and protected mice during the
first two days following challenge as follows:
Genes in group A were mainly upregulated in unprotected mice 7–14 days p.i., but unal-
tered in protected mice (Fig 3). Therefore, this gene expression is essential for a first encounter
with B. pertussis, but it is not required for protected mice.
In group A, membrane marker genes were in general related to myeloid cells (Cd300lf,
Fcgr4, Gp49a,Cd200r1,Cd302, Lair1, Sirpb1a). Other membrane marker genes are specific, for
example for neutrophils (Cxcr2, Fpr1, Fpr2) or for macrophages, such as Il1rn, killer-cell lectin-
like receptors (Klra2, Klra17), C-type lectins (Clec4a2,Clec4a3,Clec4b1,Clec4d) and mem-
brane-spanning four-domains, subfamily A (Ms4a6c,Ms4a6d,Ms4a4a,Ms4a4c). Moreover,
the expression of Cd1d1 and Cd1d2, involved in MHC Class I antigen presentation, C3ar1
(APCs, Macrophages, T-cell activation),Clmp (cell-cell adhesionmolecule), and Chl1was only
upregulated in unprotected mice. In addition, expression of some T-cell-related genes (Art2b,
Cd48) were found. Art2b is constitutively expressed on T-cells, whereas Cd48 is expressed on
multiple immune cells playing a major role in T-cell activation. Finally, podoplanin (Pdpn)
which is a lung injury marker and serves as a CD4+ effector T-cell inhibitor [19], was only
unprotected mice and in protected mice before and after challenge), Cluster IV (Differential expression in unprotected
mice and additional differential expression as result of challenge in protected mice), Cluster V (Absent in unprotected mice
but differential expression in protected mice) and Cluster VI (absent in unprotected mice but differential expression pre-
and post-challenge in protected mice). (B) Transcriptomic profiles obtained on 2 days p.i. in unprotected and 2 days p.c.
protected mice were compared by plotting all 786 genes in a scatter plot and divide the genes in different fractions based
on co-expression. The black solid lines are the thresholds for the significant FR (FR 1.5 or 0.67) compared to naive
mice (D0 unprotected) for both unprotected and protected mice. Black dots represent genes that are not significantly
regulated compared to naive mice (D0 unprotected) in both groups. The red solid lines represent the threshold for the
significant FR (FR 1.5 or 0.67) of both unprotected 2 days p.i. and protected mice 2 days p.c. All red triangles
represent genes that show significant differential expression (FR 1.5 or 0.67) between unprotected 2 days p.i. and
protected mice 2 days p.c. In total, 212 genes were differentially expressed between both groups of which 108 genes were
upregulated and 104 were downregulated. These genes were divided in eight fractions that are significantly up-regulated
(1–4) or downregulated (5–8) in protected mice compared to unprotected mice and are further specified as heatmaps in
S1B Fig. Dots with other colors (orange, green, brown, and blue) represent genes that are significantly regulated in
unprotected and/or protected mice compared to naive mice (D0 unprotected) but these genes are not differentially
regulated between unprotected 2 days p.i. and protected mice 2 days p.c. (C-D) A selection of eight terms (KEGG-
pathways and GO-BP terms) found enriched in the ORA of the 786 genes and the kinetics over time of indicated terms is
depicted. (C) Kinetics was determined by averaging the FR for each term at each time point and is expressed on LN-scale.
(D) For each enriched term, the Benjamini score and the number of upregulated (red) and downregulated (green) genes in
the protected mice and unprotected mice is shown.
doi:10.1371/journal.pone.0164027.g002
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Fig 3. Pulmonary gene expression profiles of membrane proteins and secreted proteins in protected and
unprotected mice following B. pertussis challenge. Expression profiles of genes in the lungs encoding membrane
proteins (left panel) and secreted proteins (right panel) were selected according to GO-BP terms, KEGG pathways and
text mining. Each list is divided in four groups (A-D) based on their expression profile on 4 hours and 2 days p.c. Group
A contains genes that are significantly upregulated in unprotected mice, but unaltered in protected mice. Group B
covers genes that are not upregulated on 4 hours and 2 days p.i. in unprotected mice, but are directly activated in
protected mice. Group C comprehends genes that are upregulated on 4 hours and/or 2 days p.c. in both protected and
unprotected mice. Group D includes genes that are significantly regulated from 7 days p.c. in both protected and
unprotected mice. In addition, the color codes of the six clusters from Fig 2 are added.
doi:10.1371/journal.pone.0164027.g003
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expressed in unprotected mice. Among the genes encoding secreted proteins, expression of a
number of acute inflammatory genes was altered in unprotected mice (Cp, Fn1, Il1a, Il1b, Il6,
Ptx3, Saa1, S100a9, S100a8), but not in protected mice. Some genes are involved in blood vessel
formation (Fn1, Vegfc, Vegfd) or LPS-binding (Crispld2). Furthermore, the genes of a
Th17-specific cytokine (Il17f), and mucosal chemokines attracting IgA plasmablasts (Ccl28)
and CCR7+ lymphocytes (Ccl21b) were only upregulated in unprotected mice.
The genes in group B were not expressed until 7 days p.i. in unprotected mice. However, in
protected mice, these genes were already upregulated between 4 hours and 2 days p.c. (Fig 3).
Here, higher activity of microfold cells (M-cells) was suggested by enhanced gene expression of
Gp2 and Umod. Moreover, macrophage-related genes (Basp1,Mpeg1,Ms4a7), innate-specific
receptors such as Fc-receptors (Fcgr2b, Fcer1g, Fcgr3) and genes important for function of mul-
tiple innate cells (Fnbp1, Parm1, Cdhr1) were expressed earlier in protected mice. Additionally,
gene expression of membrane markers (Vcam1, Cd22,Cd72,Cd4,Cd3g,Cxcr6,Ccr6,Art2a-ps)
demonstrated earlier adhesion of immune cells in the lungs of protected mice. It indicated early
presence of adaptive immune cells such as B-cells (Cd22,Cd72,Ccr6) and T-cells (Cd4,Cd3g,
Cxcr6,Ccr6,Art2a-ps). In total, 16 genes encoding secreted proteins were still upregulated in
protected mice before challenge, whereas seven genes were reactivated following the challenge.
These genes includedmany chemoattractants (Ccl8,Cxcl9,Cxcl12,Cxcl13,Ccl19,Glycam1,
Gm12407,Gm2023,Gm1987). Some genes are associated with attracting specific cells, such as
B-cells (Cxcl13), CXCR4+ lymphocytes (Cxcl12), CCR7+ lymphocytes (Ccl19), CD62l+ lympho-
cytes (Glycam1), CXCR3+ T-cells (Cxcl9), and CCR5+ cells (Ccl8). In addition, upregulation was
detected for genes associated with antibodies (Ighg), complement (C1qa,C1qb,C1qc), activated
macrophages (Aif1), Peyer’s patches (Pglyrp1),matrix metalloproteinases (Mmp3,Mmp12) and
an MMP inhibitor (Timp4), increasedmucus production by goblet cells (Agr2, Clca1,Clca3,
Clca4) and genes related to lipid metabolism (Apod, Pla2g2d). Expression of Pla2g2d in DCs
and macrophages is related to induction of anti-inflammatory lipid mediators [20].
Most genes in group C were upregulated early (4 hours) after challenge in protected and
unprotected mice (Fig 3). Analyzing the membrane markers, the expression of 12 genes was
still upregulated prior to the challenge of protected mice, while the other 13 genes were reacti-
vated post-challenge. The membrane marker genes in group C included a neutrophil specific
marker (Cd177), for which the expression was earlier and more intense in protected mice. A
similar observationwas found for Pigr, which traffics IgA across the epithelial barrier. The C-
type lectins (Clec4e,Clec4n), found on DCs, were detected in unprotected mice till 7 days p.i.,
but were only expressed in protected mice 4 hours p.c. The early expression of Cd14 suggests
LPS binding in both protected and unprotected mice, whereas Tlr2 is involved in pathogen rec-
ognition. Additionally, markers for antigen presentation (Cd74,H2-d1), macrophages (Msr1),
regulation of anti-inflammatory activities in murine airways (Adam8) [21], epithelial cells
(Pigr, Rab11b, Retnla), DCs (Cd209f), and the endothelial marker Plvap, which enables lym-
phocytes to enter the lungs [22], were detected in this group of genes. Among the genes encod-
ing secreted proteins, a selection of acute phase genes (Saa3, Reg3g, Lcn2) were highly
upregulated in protected and unprotected mice. However, the expression went down after 2
days p.c. whereas this continued in unprotected mice. In protectedmice,Cxcl5 remained highly
upregulated whileCxcl1,Cxcl2, and Cxcl3were expressed for a limited amount of time. The
chemokines encoded by Cxcl1,Cxcl2,Cxcl3 and Cxcl5 are involved in CXCR2+ leukocyte
recruitment. Expression of Ccl20, the chemokine attracting CCR6+ cells, was increasedmore
intensely in protected mice than in unprotected mice. In addition, genes involved in the com-
plement system (Cfb, C3, C4b), cytokine expression (Ccl2,Ccl7,Ccl17,Cxcl17), mucosal tissue
repair (Tff2), epithelial cells (Cyr61), and mast cells (5730469M10RIK / Fam213a) were
observed in both groups.
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Genes in group D were mainly up-regulated in protected and unprotected mice between 7
and 14 days p.c. The expression of these genes returned faster to basal level in protected mice
than in unprotected mice (Fig 3). Based on the membrane-related genes in group D, this phase
indicates innate and adaptive immune cells interacting with each other (Clec9a,Clec10a,
Clec12a, Il7r, Thy1, Trav3n-3). For example, genes were detected related to T-cells (Il7r, Thy1,
Trav3n-3), DCs (Clec9a,Clec10a,Clec12a), leukocytes (Lilrb4), macrophages (Igsf6) and lym-
phocytes or myeloid cells (Cd52). Group D also contained the upregulated gene Spp1. The cor-
responding protein of Spp1 is also known as osteopontin (OPN), which is produced by many
different immune cells and possessesmany immunological functions [23]. However, the
expression of this gene was not different between protected and unprotected mice.
B-cell and antibody-related signatures. The enhanced gene expression for the B-cell che-
moattractant Cxcl13, detected 7 days p.i., suggested recruitment of B-cells towards the lungs of
unprotected mice (Fig 4A). In protected mice, the expression of Cxcl13 had raised earlier at 2
days p.c. Increased expression of antibody-related genes indicated B-cell recruitment to the
lungs 14 days p.i. in unprotected mice. Higher and earlier expression of the immunoglobulin-
related genes (i.e. Igj, Igk, Ighm, Igkc) was observed in protected mice than in unprotected mice
(Fig 4A). These immunoglobulin-related genes indicated the formation of IgM, IgG and IgA
by these B-cells in the lung. Notably, a small decrease in expression of antibody-related genes
occurred 2 days p.c. in protected mice. Furthermore, genes of the classic complement pathway
were co-expressed with the immunoglobulin-related genes. Genes of B-cell inhibitory receptors
(Cd22,Cd72, Fcgr2b) were expressed slightly earlier in protected mice compared to unpro-
tectedmice. Moreover, the co-stimulatory receptor Ifitm1 was earlier and more constant in
protected mice. The upregulation of Ccl28 in unprotected mice 14 days p.i. indicated homing
of IgA producing B-cells to the mucosa. However, the expression of Ccl28was absent in pro-
tectedmice. The upregulation of Pigr, the IgA transporter on epithelial cells, suggested an
increase of IgA in the mucosa of protected and unprotected mice.
T-cell-related signatures. Gene expression of T-cell-related markers (Cd3g,Cd4) indi-
cated the presence of T-cells, most likely T-helper (Th) cells, in the lungs of unprotected mice
around 14 days p.i. (Fig 4B). The upregulation of Cd3g and Cd4 is still present in protected
mice prior to the challenge. The enhanced RNA levels remain high during challenge of these
mice. In addition, multiple T-cell-related genes (Il7r, Cxcr6,Thy1) were upregulated 14 days p.
i. in unprotected mice. The expression in protected mice was observed earlier at 7 days p.c.,
indicating a faster recall of memory T-cell responses. Expression of the IL-7 receptor gene
(Il7rI) indicated the presence of memory T-cells. The Th17 specific cytokine gene (Il17f) was
significantly upregulated in unprotected mice, but unaffected in protected mice. Resistin-like
alpha (Retnla) was earlier expressed by epithelial cells in protected mice, and the expression
was already diminished 7 days p.c. Resistin-like alpha stimulates Th17 responses [24].
Antigen presentation. Genes related to MHC class I and II were upregulated in unpro-
tectedmice following the challenge (Fig 4C). Whereas enhancedMHC-I expression was
observedduring the whole course of the challenge, MHC-II expression was found upregulated
7–14 days p.i. In protected mice, genes related to both antigen-presenting pathways were
expressed at every time point and decreased 14 days p.c.
Genes not previously described in the context of immunity against B. pertussis. Some
genes showed increased expression in response to B. pertussis challenge, but limited or no
information is available about their function (Fig 4D). The expression of most of these genes
was induced during the adaptive phase in unprotected mice and persisted in protected mice
after challenge. Therefore, these genes may play an important role in immunity against B. per-
tussis. These genes include members of the SPEER-family (4930572o03rik,Speer7-ps1, Speer4b,
Speer4c, Speer4e,Gm5862,Gm9758), chloride channel calcium activated channels (Clca1,
Signatures of Infection-Induced Pertussis Immunity
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Fig 4. Pulmonary gene expression profiles of genes related to T-cells, B-cells, MHC-I and II and novel genes in
protected and unprotected mice following B. pertussis challenge. Expression profiles of genes in the lungs related to
(A) T-cells, (B) B-cells, (C) and antigen presentation by MHC-I and MHC-II were selected according to GO-BP terms,
KEGG pathways and text mining. In addition, genes with unknown or poorly understood function that showed interesting
gene expression profiles in protected mice were listed as (D) novel genes. Additionally, the color codes of the six clusters
from Fig 2 are added.
doi:10.1371/journal.pone.0164027.g004
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Clca3,Clca4), microRNAs (Mir142,Mir147,Mir5117), a transcription factor (Akna), and X-
linked lymphocyte-regulated genes (Xlr4a, Xlr4b). Significant expression of cell proliferation
marker Ki-67 was found in unprotected mice, but unaffected in protected mice. Moreover, the
expression of M-cell specific genes (Gp2,Umod), an effector protein of CD4+ CD25+ regulatory
T-cells (Pla2g2d) [25], and of Glycam1, Pglyrp1, and Retnla were expressed earlier or to a stron-
ger extent in protected mice compared to unprotected mice yet their involvement is not previ-
ously described in the context of immunity against B. pertussis.
Modulated Cytokine Levels in Lung Tissue Extract
The protein concentrations of 32 cytokines in the lungs were analyzed. The concentrations of
thirteen cytokines significantly changed following a B. pertussis challenge in protected and
unprotected mice (Fig 5). CCL4 was decreased in protected mice 10 days p.c. (Fig 5A). CCL11
decreased in unprotected mice until 14 days p.i. and in protected mice until 2 days p.i. (Fig 5B).
Moreover, a significant decrease occurred for VEGF in unprotected mice between 2–7 days p.
i., which was less dramatic in protected mice (Fig 5C). In unprotected mice, G-CSF concentra-
tions were elevated 7 days p.i. In protected mice, higher concentrations of G-CSF were found
already at 4 hours and 2 days p.c. (Fig 5D). Both CXCL1 and CXCL2 were enhanced in unpro-
tectedmice, whereas only CXCL1 was significantly increased 4 hours p.c. in protected mice
(Fig 5E and 5F). CXCL5 was significantly induced in unprotected mice and remained elevated
until 7 days p.i. (Fig 5G). CXCL9, CXCL10 and IL-17A were elicited 14 days p.i. in unprotected
mice, but they were absent in protected mice (Fig 5H–5J). IL-5, TNFα and M-CSF were pro-
duced in the lungs of protected mice 4 hours p.c., but not in unprotected mice (Fig 5K–5M).
Enhanced Cytokine Levels in Mouse Serum
The concentrations of 33 cytokines were analyzed in serumof protected or unprotected mice
before and following the B. pertussis challenge. Only for seven of these, significant alterations
in their levels were found upon challenge (Fig 6A). The concentrations of CXCL1 (KC) and
CCL11 (Eotaxin) were increased 4 hours p.i. in unprotected mice. Higher concentrations of
both IL-6 and G-CSF were detected 7 days p.i. in unprotected mice. A decrease in both
CXCL10 and IL-13 occurred between 7–14 days p.i. in protected mice. B lymphocyte chemoat-
tractant (BLC) CXCL13 was elevated 14 days p.i. in unprotected mice and unaltered in pro-
tectedmice. Overall, serum cytokines present during infection of unprotected mice are
unaltered during the challenge of protected mice. In conclusion, these results indicate that sys-
temic signals for pro-inflammatory cytokines (CXCL1 and IL-6) and recruitment of B-cells
(CXCL13), T-cells (CCL11 and CXCL10) and neutrophils (CXCL1, G-CSF) are not required in
protected mice during a challenge with B. pertussis.
Cellular Composition Spleen
In unprotected mice, neutrophils (Gr1+) play an important role in the clearance of bacteria
from the lungs and are often used as marker of disease. This process is characterized by a grad-
ually increased percentage of neutrophils in the spleen between 4 and 21 days p.i. [10]. Analysis
of the percentage Gr1+ cells in the spleen following challenge in protected mice indicated that
this recruitment of granulocytes did not occur 14 days p.c. whereas the drastic increase of gran-
ulocytes in unprotected mice was again observed (Fig 6B). Together, these results show that
recruitment of circulating granulocytes/neutrophils occurs only in unprotected mice after a
challenge.
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Fig 5. Cytokine profiles in the lungs following B. pertussis challenge in unprotected and protected mice.
Pulmonary concentrations of (A) CCL4, (B) CCL11, (C) VEGF, (D) G-CSF, (E) CXCL1, (F) CXCL2, (G) CXCL5, (H)
CXCL9, (I) CXCL10, (J) IL-17A, (K) IL-5, (L) TNFα and (M) M-CSF were analyzed before and after a B. pertussis
challenge in unprotected (lighter blue bars) and protected (dark blue and red bars) mice, as indicated. Data represented as
mean concentrations of individual values (n = 3). Significant values were calculated by one-way ANOVA with multiple
comparison compared to the pre-challenge level (D0) of unprotected mice or protected mice (* = p<0.05, ** = p<0.01, and
*** = p<0.001, **** = p<0.0001).
doi:10.1371/journal.pone.0164027.g005
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Fig 6. Serum cytokine profiles and percentage of splenic neutrophils following B. pertussis
challenge in unprotected and protected mice. (A) The serum concentrations of 33 cytokines were
analyzed before and after a B. pertussis challenge in unprotected (lighter blue bars) and protected (dark blue
and red bars) mice, as indicated. Concentrations of CXCL13, CCL11, CXCL1, G-CSF, IL-6, CXCL10, and IL-
13 serum were significantly altered and represented as mean concentrations of individual values (n = 3).
Significant values were calculated by one-way ANOVA with multiple comparison compared to the pre-
challenge level (D0) of unprotected mice or protected mice (* = p<0.05, ** = p<0.01, and *** = p<0.001). (B)
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B. pertussis-Specific Antibody Responses in Serum and Lung Tissue
Extract
Levels of IgA, IgG, and IgG subclasses were determined just before and after 14 days challenge
in sera of unprotected and protected mice (Fig 7A–7E) B. pertussis outer membrane vesicles
(OMV) and purified antigens (Prn, Ptx, FHA, and Fim2/3) were used as coating antigen. Only
anti-OMV antibodies were induced in unprotected mice 14 days p.i., while antibodies against
purified antigens could not be detected. Antibodies specific for all five purified antigens were
observed in protected mice before challenge (D0).
After the challenge, anti-Ptx IgG and IgA levels dropped in protected mice, whereas the
anti-OMV and anti-FHA IgG levels remained high. Moreover, the anti-Prn IgG1 and IgA lev-
els decreased,while IgG2a and IgG2b levels increased. Notably, serum IgA levels against Fim2/
3 were only detected in protected mice 14 days p.c. In addition to systemic antibody levels, the
local formation of IgA antibodies was determined in lung lysates (Fig 7F). Challenge in unpro-
tectedmice elicited mainly anti-OMV IgA, which was detected 14 days p.i.
In protected mice, anti-OMV IgA antibodies were present before challenge (D0) and were
further increased 14 days p.c. Anti-Prn and anti-Fim2/3 IgA remained elevated, while anti-Ptx
IgA decreased. Combined data of all time points showed a gradual increase of pulmonary anti-
OMV IgA levels post-challenge in protected mice (Fig 7G). Western blotting and mass spec-
trometry was used to determine the antigen specificity of the anti-OMV IgA antibodies in pro-
tectedmice before (D0) and after the challenge (D14) (Fig 7H). The IgA antibodies on D0 were
solely directed against Vag8. Notably, challenge of protected mice led to strong anti-LPS IgA
antibody formation, whereas the level of anti-Vag8 antibodies remained unaltered (Fig 7H).
Specific CD4+ T-Cell Response in the Spleen
After challenge, the presence and type of B. pertussis antigen-specificmemory CD4+CD44+ T-
cells in the spleen were determined. The cytokine production of CD4+ T-cells was analyzed
according to the study design depicted in Fig 8A on single cell level and in culture supernatants
after stimulation of splenocytes with Ptx, FHA, or Prn. The CD4+ T-cell response was deter-
mined after primary infection of unprotected mice 10 days and 66 days p.i. (-D46 and D10,
respectively). Primary infection led to increased percentages of IFNγ- and IL-17A-producing
Prn-specificCD4+ T-cells on 10 days p.i. (-D46), which percentages significantly increased 66
days p.i. (D10). In addition, IFNγ- and IL-17A-producing FHA-specific CD4+CD44+ T-cells
could be detected on this time point (Fig 8B). Protected mice received an intranasal B. pertussis
challenge 56 days after the primary infection (D0) and showed increased percentages of IFNγ-
and IL-17A-producing Prn-specificCD4+ CD44+ T-cells on 10 days p.c. compared to the per-
centage in naive mice. Notably, the percentage IL-17A-producing Prn-specificCD4+ CD44+ T-
cells in these challenged protected mice 10 days p.c. was increased compared to the percentage
in the unprotected mice on that time point (Fig 8B).
Cytokine levels in culture supernatant revealed that 10 days p.i. (-D46) splenocytes showed
a moderate production of IL-5 and IFNγ after stimulation with Ptx and FHA, respectively (Fig
8C). In unprotected mice that were sacrificed 66 days p.i. (D10), Prn-stimulation resulted in
enhanced production of IL-5, IL-13, and IL-17A while production of IL-17A was also observed
after Ptx stimulation. FHA stimulation caused production of IL-4, IL-5, IL-13, TNFα, IL-17A,
and IL-10. Data obtained in protected mice 10 days p.c. revealed the induction of IL-5, IL-13
The percentage of Gr1+ cells (neutrophils) was determined over time in the spleen of unprotected and
protected mice by using Flow cytometry (* = p<0.05).
doi:10.1371/journal.pone.0164027.g006
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and IL-17A after Prn-stimulation, increase in IFNγ- and IL-17A after Ptx-stimulation, and
production of IL-5, IL-13, IFNγ, TNFα, IL-17A and IL-10 after FHA-stimulation. In conclu-
sion, infection-inducedT-cell responses were Th1 and Th17 mediated. Additionally, challenge
of protected mice did not result in a dramatic booster of the CD4+ T-cell response, since only a
Fig 7. Serum and pulmonary antibody profiles in unprotected and protected mice following B. pertussis challenge. Serum IgA,
IgG, and IgG subclass responses specific for (A) OMV, (B) Ptx, (C) Prn, (D) FHA, and (E) Fim2/3 were determined by using a MIA. Data
were obtained in naive mice and protected mice prior to challenge (D0) and 14 days post infection (p.i.) or 14 days post-challenge (p.c.)
(n = 3/time point). (F) Pulmonary IgA responses against these antigens were determined on the same time points. * = p<0.05
experimental group versus unprotected group (D0), + = p<0.05 protected group (D0) versus protected group (14 days p.c.). (G) The
kinetics of the anti-OMV IgA antibody formation in lung lysates were analyzed at more time points (n = 3/time point) and expressed in
fluorescence intensity (F.I.). **** = p<0.0001, challenged unprotected or protected group versus unprotected or protected group (day
0), ++ and +++ = p<0.01 and p<0.001 unprotected group versus protected group (for each time point). (H) Western blot on separated B.
pertussis B1917 proteins was performed with pooled lung lysates (1:50) of unprotected and protected mice prior to challenge (D0), and
of protected mice 14 days p.c. with IR800-labeled secondary antibody. Left panel shows whole protein range (260kDa-<10kDa) of B.
pertussis lysate. Right panel shows more detailed separation of the 110-60kDa protein range. Antigen identification for Vag8 and LPS is
depicted.
doi:10.1371/journal.pone.0164027.g007
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higher percentage of IL-17A-producing CD4+CD44+was observed in protected compared to
unprotected mice
Discussion
A Bordetella pertussis infection in mice or baboons causes sterilizing immunity [7, 10]. There
are strong indications that the Th1/Th17 responses and mucosal IgA are major contributors to
Fig 8. Systemic T-cell responses in unprotected and protected mice. (A) Study design is depicted for the collection of
splenocytes in two different experiments (-D46 and D10). The first experiment (-D46) included unprotected mice 10 days p.i.
and naive mice. The second experiment (D10) included unprotected mice 66 days p.i., protected mice 10 days post-
secondary challenge, and naive mice. Splenocytes were in vitro restimulated with Prn, FHA or Ptx for 8 days. (B) The
percentages of IFNγ-, IL-5-, and IL-17A-producing CD4+CD44+ T-cells were determined using ICS (n = 6). (C) Cytokine levels
of IL-4, IL-5, IL-10, IL-13, IL-17A, IFNγ, and TNFα in supernatant after 7 days of stimulation were determined by using a MIA.
Results (mean of n = 6) are corrected for the background level in the presence of medium as control. Statistical differences
between the groups were detected for the ICS with a non-parametric Mann-Whitney test and for the MIA with a Student t-test
on the log-transformed data. * = p<0.05 experimental group versus naive group, # = p<0.05 protected group (D10) versus
unprotected group (D10).
doi:10.1371/journal.pone.0164027.g008
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this superior protection [10–12]. Nevertheless, many immunological responses caused upon a
B. pertussis infection are still not discovered. In the current study, protected and unprotected
mice were challenged intranasally with B. pertussis after which innate and adaptive immuno-
logical signatures were identified associated with the infection-inducedand excellent immunity
in mice.
Protected mice had high levels of B. pertussis-specific serum IgG, mucosal IgA in the lungs
and Th1/Th17 cells in the spleen, whereas unprotected mice have not. In addition, pulmonary
molecular signatures in the protected mice revealed unique markers of B-cells, T-cells, and
immunoglobulins, implying the presence of tissue-resident adaptive immune cells in the lungs.
Moreover, molecular signatures of myeloid and mucosal-specific cells, such as mast cells and
goblet cells were present. Interestingly, 320 genes were still differentially expressed before the
challenge in protected mice as result of the first infection, as compared to unprotected mice
before challenge. Since bacteria were cleared from the lungs 28 days after primary infection
[10], the question was raised what is the source responsible for this upregulation. Possibly, a
change in the cellular composition of the lungs due to residence of new innate and adaptive
immune cells result an aberrant gene expression profiles. Importantly, the overall transcrip-
tomics data indicate not only a relatively persistent and broadly altered adaptive pulmonary
immune status but also maintained innate changes in protected mice in comparison to their
naive counterparts.
Pathogenesis of pertussis in non-vaccinated individuals is characterized by prolonged bacte-
rial presence and severe lung tissue distress and damage [26]. It is hypothesized that immune
evasion strategies of B. pertussis [27] extend residence time. Ideally, pre-existing immunity
induced by vaccination should provide fast clearance of pertussis bacteria and long-lasting
immunity to avert bacterial transmission [7] and limit respiratory tissue damage. The absence
of pro-inflammatory responses and neutrophil circulationmay be signs of less severe disease.
Protected mice, in contrast to unprotected mice, had reduced systemic serum cytokine secre-
tion, including the pro-inflammatory cytokine IL-6 and neutrophil attractants (CXCL1 and
G-CSF), and no induction of neutrophils in the spleens. Additionally, selective innate molecu-
lar signatures were absent in the lungs of protected mice following the B. pertussis challenge.
This included genes encoding pro-inflammatory cytokines such as Il1a, Il1b, Il6 and Saa1 as
part of the acute phase response. Moreover, enhanced gene expression of the KLR and CLEC-
family, was not detected in protected mice. KLR and CLEC genes may harbor similar functions
[28], which are specifically found on myeloid cells [29] and play an important role in tissue
infiltration of neutrophils following inflammation [30]. This lack of expression in protected
mice implies that myeloid cells expressing these membrane markers are not required for the
sterilizing immunity. Finally, the enhanced cell proliferation in the lungs of unprotected mice,
based on the high expression of Ki-67, was absent in protected mice. Overall, the altered tran-
scriptomes in the lungs of protected mice suggest that these mice are able to control the chal-
lenge locally without alarming systemic pro-inflammatory signals.
The acquired immune status of the protected mice enables an alternative solution for fast
bacterial clearance with limited systemic recruitment of immune cells from the circulation.
Specificmarkers (IL-5, TNFα and M-CSF) were exclusively present in the protected mice,
which may contribute to the sterilizing immunity. Early secretion of IL-5 indicates the presence
of type II innate lymphoid cells (ILCs) or antigen specific Th2-cells in the lungs. Both Th2-cells
[31] and ILCs [32] can play a role in protection during the innate phase. However, no B. pertus-
sis-specific Th2-cell formation was detected in the spleen of protected mice. The presence of
ILCs is indicated by gene expression of Thy1 and Il7r [33]. Therefore, IL-5 could be produced
by type II ILCs. These type II ILCs also promote early antibody responses in the lung [34].
While pulmonary innate immune cells still play a role during the challenge of protected mice,
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some of these cells signatures (i.e.Gp2,Umod, Pglyrp1,Clca3) were also highly active prior to
the challenge. The pulmonary expression of Gp2 and Umod was increased in protected mice
prior and post-challenge. Glycoprotein 2 (GP2) and uromodulin (Umod) are expressed on
microfold cells (M-cells) [35]. M-cells facilitate the uptake of antigens at the mucosal site and
the subsequent transportation across the epithelial barrier. GP2 serves as a receptor for muco-
sal antigen and binds adhesins on Fim+ bacteria [36], such as B. pertussis. Simultaneously,
expression of peptidoglycan recognition protein 1 (Pglyrp1) was detected, which at the intesti-
nal mucosal site is found in Peyer’s patches co-localizedwith M-cells [37]. This indicates that
the M-cells are either increased in number or more active in protected mice prior and post-
challenge. At the pulmonary site, M-cells are commonly found in the Bronchus-Associated
Lymphoid Tissue (BALT) [38] gathered with tissue-resident adaptive cells, such as B-cells and
T-cells, facilitating a more efficient antigen presentation. This suggests that the local pulmo-
nary immunity induced by a primary B. pertussis challenge is a result of not only the induction
of acquired immunologicalmemory, but also increased innate activity and subsequent inter-
play between of innate and acquired immune cells in the BALT. Enhanced expression of genes
specific for goblet cells (mucus-producing cells), such as chloride channel calcium activated
channels (Clca1,Clca3 and Clca4) and anterior gradient 2 (Agr2) [39] suggests that these cells
are more active during the challenge in protected mice. Goblet cells can also orchestrate local
immune responses. For instance, IL-17 and CXCL-1 induction in the lungs and leukocyte
recruitment are modulated by CLCA3 in mucus cells [40].
Myeloid cells play an important role in clearance of B. pertussis. For instance, a large neutro-
phil influx into the lungs occurs during the challenge of unprotected mice [10, 41]. Neutrophils
are essential for phagocytosis and may serve as a marker for disease like white blood cell counts
for baboons and young infants [42, 43]. Myeloid cells expressing membrane markers of the
KLRs, CLECs and the MS4A family [28, 29, 44] were absent in the protected mice after the
challenge. However, the enhanced gene expression of the neutrophil-specificCd177 and mac-
rophage-specificMpeg1 suggests involvement of other subsets of myeloid cells during the chal-
lenge in protected mice. The expression of CD177 on neutrophils is enhanced in the presence
of G-CSF [45] which was also detected in the lungs of protected mice. These signatures could
be related to changes in the pulmonary cell composition as a result of the first infection. For
example, opsonization of bacteria by pre-existing specific antibodies and the subsequent
phagocytosis by different myeloid cells enables an enhanced clearance of bacteria. In addition,
the outgrowth of bacteria is absent in protected mice after challenge. Hence, the total number
of phagocytes required for removal of bacteria is expected to be lower. Finally, the infection-
induced immunity might result in signatures of airway specific cells, such as was detected for
alveolar macrophages. Both GC-CSF and M-CSF play an important role in proliferation and
differentiation of alveolar macrophages [46]. In addition, pulmonary secretion of M-CSF was
detected exclusively in protected mice 4 hours p.c. This change in lung environment enables
formation of specific alveolar macrophages with a very high antigen-presenting capacity [47].
The contribution of alveolar macrophages [48] and mast-cells [49] with respect to immunity
against B. pertussis has previously been demonstrated.
Together these findings demonstrate that the infection-primed immunity resulted in the
enhanced activity of pulmonary innate cells, such as alveolar macrophages, M-cells, and ILCs.
This may indicate that these innate cells have trained innate immunity [50] that provides an
altered pulmonary innate homeostasis [51]. This different status of innate cells may contribute
to the local immunity in protected mice. Therefore, pulmonary innate cells are interesting tar-
gets for optimizing pertussis vaccination strategies, e.g. by pulmonary vaccination.
Infection-induced immunity comprised of a Th1/Th17-mediated response, as was demon-
strated by the systemic analysis of B. pertussis-specificT-cells in the spleen. After the challenge,
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these responses were recalled fast in the protected mice. Despite the upregulated pulmonary
gene expression of Cxcl9, protein secretion of CXCL9 and CXCL10 was not detectable in lung
lysates and serum of protected mice, indicating reduced recruitment of CXCR3+ T-cells. How-
ever, gene expression showed that molecular signatures of T-cells (i.e. Cd3g,Cd4,Thy1) were
further enhanced in protected mice post-challenge. This indicates the presence of tissue-resi-
dent memory CD4+ T-cells. This assumption is emphasized by the enhanced expression of the
memory T-cell marker Il7r (Cd127).Moreover, gene expression of the chemokinesCcl20 and
Cxcl12 and their corresponding receptors Cxcr6 and Ccr6 implied recruitment of different
types of T-cells, such as CCR6+ Th17-cells [52] and CXCR6+ T-cells [53] in the lungs. Lee et al.
showed that the presence of pulmonary CXCR6+ T-cells correlated with local protective immu-
nity againstMycobacterium tuberculosis [53]. Furthermore, CCR6 is an important mediator of
mucosal immunity [54], indicating a potential role for pulmonary CXCR6+ and CCR6+ T-cells
in immunity against B. pertussis. Strong B. pertussis-specificTh17 responses occur during
infection in unprotected mice, which remain present for a long period [10]. Moreover, the
Resistin like alpha (Retnla) was found to stimulate Th17 responses [24]. However, the secretion
of IL-17A and expression of Il17f in the lungs was absent after the challenge of protected mice.
This indicates either that we missed this expression due to a change in expression kinetics or
that the effector function of the Th17 cells had changed.
Protected mice had high levels of B. pertussis-specific IgG in the serum. In addition, pro-
tectedmice expressed genes encoding for B-cell markers and antibody production in their
lungs. This was confirmed by the presence of mucosal IgA in the lungs. We demonstrated that
this pulmonary IgA in protected mice is directed against Ptx, a Fim2/3 antigen mixture, and
Vag8. Interestingly, the anti-Ptx IgG and IgA antibody levels decreased after the challenge and
may have played a role in the neutralization of pertussis toxin during the second infection. The
inclusion of Fimbriae or Vag8 in pertussis vaccines may improve the efficacy. Especially target-
ing Vag8, an important virulence factor that affects complement-mediated responses [55, 56],
may significantly improve the efficacy of pertussis vaccines by enhancing opsonophagocytosis
[56–58]. IgA plays an important role in protection against B. pertussis [59]. Therefore, the
induction of mucosal IgA by mucosal vaccination might be a big advantage, especially because
IgA induction is completely absent after immunization with current pertussis vaccines [58].
Induction of B-cell-related gene expression after a challenge of protected mice shows a recall
response leading to increased antibody production. Here, CCR6 expression may be important
for memory B-cells to mount a recall response [60]. The antibody-related gene expression
showed co-expression with components of the classical complement pathway and seven genes
of the SPEER-family with unknown function, suggesting the expression of these genes occur-
ring in the B-cells. Overall, these findings demonstrate the presence of both systemic and pul-
monary humoral responses primarily directed against Ptx, Fim2/3 and Vag8. This is where the
results obtained in this study may contribute to understanding and optimizing immunity
against B. pertussis. The different pertussis vaccines, such as the acellular (aPV), whole-cell
(wPV) and outer membrane vesicle (omvPV) vaccines, evoke substantially different T-helper
cell polarization [11, 61] and humoral immunity, based on subclass responses and antigen
specificity [58]. All vaccines provide however enhanced bacterial clearance in mice as com-
pared to non-vaccinatedmice, indicating that multiple types of immunity can achieve protec-
tion against pertussis. Nonetheless, sterilizing immunity in the lungs that is seen for infection
induced-immunity [7, 10] is not provided by subcutaneous vaccination [7].
In conclusion, the comprehensive comparison of responses between protected mice and
unprotected mice resulted in detailed insight in characteristics of protective immune responses
against pertussis. The unprotected mice are largely depending on recruitment of phagocytic
cells into the lungs to remove the bacteria, whereas the acquired immunity in the protected
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mice enables fast recognition and neutralization of the bacteria. The presence of mucosal IgA
and upregulation of gene signatures related to memory Th1/Th17 cells and memory B-cells
may indicate the presence of these cells that contribute to effective immunity against B. pertus-
sis. Here, CCR6+ B-cells, Th17 cells and CXCR6+ T-cells play an important role in the B. per-
tussis infection-inducedpulmonary immunity. Moreover, high activity of ‘trained’ pulmonary
innate immune cells, such as alveolar macrophages, M-cells and goblet cells, was observed in
the lungs of protected mice. Hence, induction of pulmonary immunity e.g. achieved by local
immunization will improve the efficacy of pertussis vaccines, perhaps also on the long term. A
single dose of intranasally administered live-attenuated pertussis vaccine shows that such an
approach induces good protection in mice [62] with longer lasting immunity [63] and also
through a Th1/Th17-mediated response [64]. In conclusion, the present study showed that the
use of a systems approach enables to unravel infection-induced responses in more detail,
including the interplay between innate and acquired immune responses.
Methods
Ethics Statement
An independent ethical committee for animal experimentations (DEC) of Intravacc reviewed
the animal experiments of this study according to the guidelines provided by the Dutch Animal
Protection Act. The document of this study with the identification number ‘DPA201100348’
was approved by the committee.
B. pertussis Challenge Culture
Cultivation of Bordetella pertussis B1917 and preparation of the challenge culture was per-
formed as previously described [10].
Animal Experiments
Thirty female, 8-weeks-old, BALB/c mice (Harlan, The Netherlands) were divided in ten groups
of three animals and housed in cages (macrolon III including filter top). Six groups of naive
mice (n = 3 mice/group) were intranasally infected under anesthesia (isoflurane/oxygen),with
2x105 CFU B. pertussis B1917 in 40μl Verweij medium and left 56 days to recover. 56 days p.i.
(D0), five groups of these protected mice with infection-induced immunity and five groups of
naive (D0 unprotected) mice (n = 3) of the same age were challenged intranasally as described
above for the primary infection and euthanized at 4 hours, and 2, 7, 10 and 14 days after chal-
lenge, according to the study design in Fig 1. Additionally, 30 mice were included for two indi-
vidual experiments analyzing CD4+ T-cell responses (Experiment design in Fig 8A). On 10 days
p.i. (-D46), six primary-infectedand six complete naive mice were euthanized. On day 10 p.c.,
six mice that had encountered two infectious doses (-D56 and D0), six primary-infectedmice
(66 days p.i.), and six complete naive mice were euthanized.Mice from all groups were bled
under anesthesia (isoflurane/oxygen) by orbital bleeding and euthanized by cervical dislocation.
Collectionof whole blood, lungs and spleen were performed as describedbefore [10].
Microarray Analysis
RNA isolation from lung tissue, determination of RNA concentrations, and RNA integrity was
executed as described before [10]. Amplification, labeling and hybridization of RNA samples
to microarray chips was carried out at the Microarray Department of the University of Amster-
dam, The Netherlands, as describedpreviously [65]. Complete raw and normalizedmicroarray
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data and their MIAME compliant metadata from this publication have been submitted to the
GEO database (www.ncbi.nlm.nih.gov/geo) and assigned the identifier GSE75438.
Data Analysis of Gene Expression
Statistical analysis of gene expression data was done in R according to methods described
before [10]. Further functional interpretation, was performed using resources such as DAVID
[18], Gene Ontology, KEGG, and BioGPS. Data visualization was done in R as well as Gene-
Maths XT software (Applied Maths, Sint-Martens-Latem, Belgium).
Antibody Levels in Serum and Lung Lysate
Levels of pulmonary total IgA and serum total IgA, IgG and IgG subclass (IgG1, IgG2a, IgG2b
and IgG3) specific for B. pertussis antigens pertactin, filamentous hemagglutinin (FHA), per-
tussis toxin (Ptx), combined fimbria type 2 and 3 antigens (Fim2/3) and outer membrane vesi-
cles B1917 (OMV B1917) were determined using a multiplex immunoassay (MIA) as
describedpreviously [10].
Western Blotting Using IgA from Lung Lysate
Infrared labeling (IR800) of goat-anti-mouse IgA (Southern Biotech), protein separation by
SDS-PAGE, and immunoproteomic profiling by Western blot (1:50 dilution) and MS-MS were
performed as describedpreviously [58]. For improved separation of the 80kD-110kD range, a
4–12% Bis-Tris protein gel (NuPAGE Novex, 1.0mm 10wells, Invitrogen) was used.
Splenic Gr-1+ Cell Analysis
Determination of the percentage Gr-1+ cells in isolated splenocytes was carried out as described
before [10].
Stimulation of B. pertussis-Specific T-Cell from Spleens
Splenocytes were isolated and stimulated with 1 μg/ml Prn, Ptx or FHA in IMDM complete
medium (IMDMmedium (Gibco) supplemented with 8% FCS, 100 units penicillin, 100 units
streptomycin, 2.92 mg/ml L-glutamine, and 20 μM β-mercaptoethanol (Sigma)), or only
medium, as describedpreviously [10]. Supernatants were collected after 7 days for cytokine
analysis. After overnight stimulation with the same conditions, intracellular cytokine staining
was executed splenocytes that were stimulated for 8 days to identify CD4+CD44+ T-cells pro-
ducing IL-5, IFNγ or IL-17A.
Multiplex Immunoassay (MIA) for Cytokines
Amouse cytokine 7-plex luminex kit (Milliplex; Merck KGaA, Darmstadt, Germany) was used
to determine concentrations (pg/ml) of IL-4, IL-5, IL-10, IL-13, IL-17A, TNFα, and IFNγ in
culture supernatants of 7 days stimulated splenocytes of individual mice in a MIA. A mouse
cytokine/chemokine32-plex luminex kit (Milliplex MAPMouse Cytokine/Chemokine—Pre-
mixed 32 Plex; Merck KGaA, Darmstadt, Germany) was used to determine concentrations
(pg/ml) of Eotaxin, G-CSF, GM-CSF, IFNγ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-
17A, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC, LIF, LIX,M-CSF, MCP-1,
MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNF-α, and VEGF, in serum and lung lysates in a
MIA (according to the manufacturer’s instructions and as describedpreviously [10]). Measure-
ments and data analysis were performedwith Bio-Plex 200, using Bio-Plex Manager software
(version 5.0, Bio-Rad Laboratories).
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BLC (CXCL13) Cytokine ELISA
Serum concentration of B lymphocyte chemoattractant (BLC/CXCL13) was determined by
ELISA (Mouse BLC ELISA kit, RAB0046, Sigma-Aldrich,Germany) according to the manufac-
turer’s manual. In short, serum (50 μl) was diluted in assay buffer A (1/1; v/v) and incubated in
an antibody-coated ELISA plate (overnight, 4°C, gentle shaking). After washing four times
with 300 μl wash buffer, wells were incubated with 100 μl biotinylated antibody (1 hour, room
temperature, gentle shaking). After washing four times with 300 μl wash buffer, wells were
incubated with 100 μl streptavidin solution (45 min., room temperature, gentle shaking). After
washing four times, wells were incubated with 100 μl TMB one-step substrate reagent (30 min.,
RT) and reaction stopped with 50 μl stop solution. Finally, the absorbance was recorded at 450
nm with a plate reader (BioTek reader EL808, Bio-Tek) and converted to BLC concentration
by using a dilution series of a standard (1.37–1,000 pg/ml) and Gentech 5 software (BioTek).
Statistical Analysis
Serum and pulmonary cytokines levels were analyzed by using a one-way ANOVA with multi-
ple comparisons compared to the pre-challenge level (D0) of unprotected mice or protected
mice followed by a Dunnett t-test. ICS data was analyzed by using a Mann-Whitney t-test. For
cytokine profiling after re-stimulation of splenocytes, cellular composition of spleen, and anti-
body levels, data was first log-transformed before t-test analysis. In all corresponding figures,
p-values are represented as  = p<0.05,  = p<0.01,  = p<0.001 and  = p<0.0001.
Supporting Information
S1 Fig. Comparison of pulmonary transcriptomic profiles between unprotected and pro-
tectedmice per time point. (A) The fold ratios (FR) of all 786 differentially regulated genes
compared to non-infected naive mice for both unprotected and protected mice were portrayed
as scatter plot at all five time points. At each time point, for each gene, the FR was calculated
between unprotected and unprotected mice. All genes that were differently expressed
(FR 1.5 or0.67) were depicted in red. The number of upregulated and downregulated
genes is given for each comparison. (B) The 212 genes that were found differently expressed
(FR 1.5 or0.67) between unprotected and protected mice 2 days p.c. in Fig 2D were
divided in in eight fractions based on upregulation (1–4) or downregulation (5–8). These genes
are depicted as heatmap per fractionwith additional information on the FR of these genes in
unprotected mice and protected mice compared to non-infected naive mice.
(TIF)
S1 Table. Differentially expressed genes in the lungs of protected and unprotectedmice fol-
lowing a B. pertussischallenge.Full list of 786 genes that are differentially expressed in the
lungs of protected and unprotected mice following a B. pertussis challenge. Information
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